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Salvinorin A, the active component of the hallucinogenic
sage Salvia divinorum, is an apparently selective and highly
potent -opioid receptor (KOR) agonist. Salvinorin A is
unique among ligands for peptidergic G protein-coupled
receptors in being nonnitrogenous and lipid-like in charac-
ter. To examine the molecular basis for the subtype-selective
binding of salvinorin A, we utilized an integrated approach
using chimeric opioid receptors, site-directed mutagenesis,
the substituted cysteine accessibility method, and molecular
modeling and dynamics studies. We discovered that helix 2 is
required for salvinorin A binding to KOR and that two resi-
dues (Val-108(2.53) and Val-118(2.63)) confer subtype selec-
tivity. Intriguingly, molecular modeling studies predicted
that these loci exhibit an indirect effect on salvinorin A bind-
ing, presumably through rotation of helix 2. Significantly,
and in agreement with our in silico predictions, substituted
cysteine accessibility method analysis of helix 2 comparing
KOR and the -opioid receptor, which has negligible affinity
for salvinorin A, revealed that residues known to be impor-
tant for salvinorin A binding exhibit a differential pattern of
water accessibility. These findings imply that differences in
the helical orientation of helix 2 are critical for the selectivity
of salvinorin A binding to KOR and provide a structurally
novel basis for ligand selectivity.
Salvia divinorum, a member of the sage family, is a halluci-
nogenic plant that has been used for traditional spiritual pur-
poses by Mazatec shamans of Oaxaca, Mexico (1, 2). More
recently, S. divinorum leaves and extracts have been used as
legal hallucinogens in the United States. The active compound
of S. divinorum is the neoclerodane diterpene salvinorin A,
which is comparable in potencywith the synthetic hallucinogen
lysergic acid diethylamide (3, 4). Following extensive screening
of the receptorome, we identified the -opioid receptor (KOR)2
as the molecular target of salvinorin A (5). Salvinorin A has
negligible affinity for all other tested G protein-coupled recep-
tors (GPCRs), including the - and -opioid receptors (MOR
and DOR), as well as serotonin 5-HT2A receptors (5, 6), which
represent the molecular target for classical hallucinogens (7).
Salvinorin A is both pharmacologically and chemically
unique in that it represents the first nonnitrogenous, naturally
occurring KOR-selective agonist and the only known nonalka-
loidal hallucinogen. Given that salvinorin A lacks the basic
amino group present in all other KOR-selective ligands (for a
review, see Ref. 8), ionic interactions are unlikely to stabilize
salvinorin A in the binding pocket of KOR (9, 10). This has led
to the hypothesis that salvinorin A binding at KORmay involve
novel ligand-receptor interactions that utilize distinct residues
within a conserved ligand binding pocket (10).
Site-directed mutagenesis and molecular modeling studies
have been widely used to gain insight into the mechanisms of
receptor-ligand binding interactions (11–14). In fact, recent
mutagenesis and molecular modeling studies have demon-
strated that salvinorinA is stabilized in theKORbinding pocket
via hydrophobic and hydrogen bonding interactions with Gln-
115(2.60) and Tyr-119(2.64) in TM2 and Tyr-313(7.36) and
Tyr-320(7.43) in TM7 (9, 10). As expected, mutation of the
highly conserved Asp-138(3.32) in TM3, which is thought to
form an ionic interaction with the positively charged amino
group of opioid ligands (8), did not markedly alter salvinorin A
binding (9). Interestingly, most of the hydrophobic and hydro-
gen binding loci are conserved among KOR, DOR, and MOR,
suggesting that there is considerable overlap in the salvinorin A
binding pocket across all opioid receptor subtypes. This finding
that salvinorin A utilizes conserved residues for binding fails,
however, to explain the molecular basis for the exquisite sub-
type selectivity of salvinorinA. Based on these observations, it is
tempting to speculate that receptor subtype differences in the
orientation of transmembrane helices may preclude salvinorin
A-receptor binding interactions in DOR and MOR.
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In the absence of direct crystallographic data, the substituted
cysteine accessibilitymethod (SCAM) has been used to provide
structural information on residues that line the ligand-binding
pocket of G protein-coupled receptors, including the D2 dopa-
mine receptor (15–18) as well as the opioid receptor family
(19–21). In the present study, we utilized a combination of
approaches to elucidate the molecular determinants essential
for the subtype-selective binding of salvinorin A to KOR. To
this end, we constructed an extensive series of chimeric opioid
receptors wherein transmembrane segments and loop regions
of the “salvinorin A-sensitive” KOR and the “salvinorin A-in-
sensitive” DOR and MOR were exchanged in order to identify
receptor domains involved in stabilizing salvinorin A binding
interactions. The receptor subtype selectivity of salvinorin A
was further examined using site-directed mutants of KOR and
molecular modeling studies of the salvinorin A-KOR binding
complex. We now report that TM2 and, to a lesser extent, the
E2 loop of KOR are essential for the selective binding of salvi-
norin A to KOR. We also report that Val-108(2.53) and Val-
118(2.63) in TM2 are critical in conferring the subtype-selec-
tive binding of salvinorin A to KOR. Most importantly, SCAM
analysis of TM2 in KOR and DOR revealed marked differences
in the water accessibility of residues known to be involved in
salvinorin A binding. These observations are consistent with
molecular modeling studies that predict a helical rotation of
TM2 is critical for the subtype selectivity of salvinorin A.
EXPERIMENTAL PROCEDURES
Materials—[3H]Diprenorphine was obtained from Perkin-
Elmer Life Sciences (53 Ci/mmol). The standard reagents, unless
otherwise stated, were purchased from Sigma. Salvinorin A was
obtained from two sources, including the Salvia divinorum
Research and Information Center (Malibu, CA) and Dr. Thomas
Prisinzano (University of Iowa). MTSEA was purchased from
Anatrace, Inc. (Maumee, OH).
Cell Culture and Transfection—Human embryonic kidney
(HEK) 293T cells were maintained in Dulbecco’s modified
Eagle’smedium supplementedwith 10% fetal bovine serum and
1 mM sodium pyruvate (Invitrogen) and were grown in a
humidified incubator in the presence of 5%CO2 at 37 °C. Tran-
sient transfection (48 h) of wild-type, chimeric, and mutant
receptor cDNAs was performed in 10-cm tissue culture plates
using Lipofectamine 2000 (Invitrogen) or EasyTransgater
DNA/RNA transfection reagent (America Pharma Source) fol-
lowing the manufacturer’s protocol.
Chimeric Receptor Constructs and Site-directedMutagenesis—
ThehumanKOR andMOR cDNAs cloned into themammalian
expression vector pcDNA3.1 (Invitrogen)were obtained from
theUMRcDNAResourceCenter (GenBankTM accession num-
ber AF498922 and AY521028, respectively). The mouse DOR
cDNA (GenBankTM accession number L07271) was a generous
gift from Dr. Mark von Zastrow (University of California, San
Francisco). Site-directed mutagenesis was performed using the
QuikChange mutagenesis kit (Stratagene) according to the
manufacturer’s protocol. Amino acids were labeled as described
previously (14, 19). The DOR (L110(2.65)C-A98(2.53)C) cysteine
mutants were constructed using the wild-type DOR template,
whereas the KOR (L120(2.65)C-V108(2.53)C) cysteine mutants
were constructed using theMTSEA-insensitiveC315(7.38)SKOR
template. These cysteine mutants were subsequently subcloned
into the pBabePuro retroviral vector (22) for transient expression
in HEK 293T cells. The incorporation of receptor mutations was
verifiedusingPCR-based, automatedDNAsequencing (Cleveland
Genomics (Cleveland,OH) andBiotic Solutions (NewYork,NY)).
The generation of cross-subtype KOR-DOR and KOR-MOR
chimeras was completed using an overlapping PCR-based
method. For this cloning strategy, the DNA primers (Invitrogen)
were designed with 20 nucleotides complementary to the KOR
cDNA at the junction sites listed below and an additional 20
nucleotides of overhang that were complementary to the DOR
or MOR cDNAs at the appropriate splicing site. The initial
receptor fragmentswere amplified using PCRunder the follow-
ing conditions: initial denaturation at 95 °C (45 s) and then 30
cycles of 95 °C (45 s), 50 °C (45 s), and 72 °C (1.5 min), followed
by a terminal extension at 72 °C (10 min); 100 ng of plasmid
DNA, 0.75 M each primer, 500 M deoxyribonucleoside
triphosphates (Roche Applied Science), 1 unit of Pfu Turbo
DNA polymerase (Stratagene). The resulting PCR fragments
were purified from a 1–2% agarose gel using the QIAquick gel
extraction kit (Qiagen) and combined for subsequent rounds of
PCR. The 20 nucleotide overhangs allowed the KOR and
DOR/MOR fragments to anneal to each other, resulting in the
recombination of KOR-DOR and KOR-MOR cDNAs at the
engineered splice sites. The annealed DNA fragments served as
the template for the second round of PCR, which was com-
pleted as described above except that the first five cycles were
completed in the absence of primers to allow for extension of
the annealed KOR-DOR and KOR-MOR fragments.
The resulting KOR(TM1–4,E2L)-DOR(TM5–7) chimera
encoded amino acidsMet-1 toMet-226 of KOR and Lys-214 to
Ala-372 ofDOR, and theDOR(TM1–4,E2L)-KOR(TM5–7) chimera
encoded amino acidsMet-1 to Thr-213 of DOR and Lys-227 to
Val-380 of KOR. The KOR-DOR(TM1) chimera encoded amino
acidsMet-1 toArg-76 ofDOR (N-terminus toTM1) and amino
acidsTyr-87 toVal-380 ofKOR (I1 loop to theC terminus). The
KOR-DOR(TM2) chimera encoded amino acids Met-1 to
Arg-86 (N-terminus to TM1) and Tyr-119 to Val-380 (E1 loop
to the C terminus) of KOR and amino acids Tyr-77 to Lys-108
of DOR (I1 loop to TM2). The KOR-DOR(TM4) chimera
encoded amino acids Met-1 to Pro-172 (N terminus to the I2
loop) and Leu-196 to Val-380 (E2 loop to the C terminus) of
KOR and amino acids Ala-163 to Val-185 (TM4) of DOR. The
KOR-DOR(E2L) chimera encoded amino acidsMet-1 toVal-195
(N terminus to TM4) and Lys-227 to Val-380 (TM5 to the C
terminus) of KOR and amino acidsMet-186 toThr-213 ofDOR
(E2 loop). The salvinorin A-rescue chimera DOR-KOR(TM1)
encoded amino acids Met-1 to Arg-86 (N terminus to TM1) of
KOR andTyr-77 toAla-372 (I1 loop to theC terminus) ofDOR.
The DOR-KOR(TM1,TM2) chimera encoded amino acids Met-1
to Val-118 of KOR (N terminus to TM2) and amino acids Tyr-
109 to Ala-372 of DOR (E1 loop to the C terminus). The DOR-
KOR(TM2,E2L) chimera encoded amino acids Met-1 to Arg-76
(N-terminus to TM1), Tyr-109 to Val-185 (E1 loop to TM4),
and Lys-214 to Ala-372 (TM5 to the C terminus) of DOR and
amino acids Tyr-87 to Val-118 (I1 loop to TM2) and Leu-196 to
Met-226 (E2 loop) of KOR. The MOR-KOR(TM2,E2L) chimera
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encoded amino acids Met-1 to Thr-103 (N-terminus to the I1
loop), Tyr-130 to Phe-206 (E1 loop to TM4), and Lys-235 to
Pro-400 (TM5 to the C terminus) of MOR and amino acids
Ala-93 to Val-118 (TM2) and Leu-196 to Met-226 (E2 loop) of
KOR. The sequence of engineered receptors was verified using
PCR-based, automated DNA sequencing (Cleveland Genomics
(Cleveland, OH) and Biotic Solutions (New York, NY)).
Radioligand Binding Assays—Forty-eight hours after trans-
fection, crudemembraneswere preparedby scraping and triturat-
ing transfected cells in standard binding buffer (SBB) (50mMTris-
HCl, 10 mM MgCl2, and 0.1 mM EDTA, pH 7.4), followed by
centrifugation at 15,000  g for 15 min. The membrane pellets
were immediately frozen and stored at 80 °C until use. Radioli-
gand binding assays were completed in duplicate using 96-well
assayplates, and reagentswereadded in the followingmanner: 100
l of SBB, 250 l of vehicle (SBB) or 2 test ligands (salvinorin A
or naloxone) diluted in SBB and spanning 6 orders of magnitude
from0.01 to 10,000 nM, 50l of 10 [3H]diprenorphine (0.2 nM
final concentration), and 100l of cellmembranes diluted in SBB.
Saturation binding assays were completed as described above
using eight [3H]diprenorphine concentrations ranging from
0.02 to 2 nM in the presence or absence of 10 M naloxone to
determine nonspecific binding. The binding reactions were incu-
bated for 1.5 h at room temperature and terminated by filtration
through Whatman GF/C filters. Radioactivity was determined
using a Beckman Coulter LS6500 scintillation counter.
Substituted Cysteine Accessibility Method—These experi-
ments were completed as previously described (19, 20).
KORModeling and Ligand Docking—Modeling studies were
performed using SYBYL (version 7.1; Tripos Associates, Inc.,
St. Louis, MO). Initial receptor models described in this work
are derived from our previously published KOR-salvinorin A
interaction model (10). In order to explore the possible role of
Val-2.63118 in our KORmodel, an extracellular portion of TM2
(Met-112(2.57) to Met-121(2.66)) was rotated so as to position
Val-118(2.63) to interact either with the ligand directly or with
othernearby features of theKOR,particularly theE1 andE2 loops.
Two separate rotationswere applied to the extracellular portionof
TM2 in our KOR model using a SYBYL Programming Language
script developed in house. The overall rotation of this part of TM2
was performed as two separate rotations rather than one to pre-
vent severe distortions at the TM2-E1 loop interface. For the first
of the two rotations, an axis of rotation was defined by residues
Ile-96(2.41) to Val-108(2.53) (Axis 1). Residues Met-112(2.57) to
Met-121(2.66)were then rotatedby30.0° aboutAxis 1 (counter-
clockwise when looking at the extracellular portion of the KOR
from the extracellular space), positioning these residues closer to
TM1 and reorienting the Val-118(2.63) side chain toward TM3.
For the second rotation, an axis of rotation was defined using res-
idues Met-112(2.57) to Met-121(2.66) (Axis 2). Met-112(2.57) to
Met-121(2.66)were then rotatedby45.0° aboutAxis 2, such that
the side chain of Val-118(2.63) was positioned between the bind-
ing site and the TM2-TM3 interfacial region.
Upon completion of the rigid helix rotations, the side chain
conformations of residues Pro-56 to Gly-73 on TM1 and Met-
112(2.57) to Met-121(2.66) on TM2 were reassigned using
SCWRL 3.0 (23). The model was then subjected to energy mini-
mization using the Tripos force field incorporating Gasteiger-
Hückel chargeswith a distance-dependent dielectric constant 4
and a nonbonded cut-off  8 Å to a gradient of 0.05 kcal/(mol 
K).The resultingmodel possessed a helix irregularity in the helical
backbone structure at Met-2.57112-Pro-2.58113, indicated by the
ribbon backbone trace as rendered by the MOLCAD facility
within SYBYL. The loop search facility within SYBYL was thus
used to find a suitable replacement for the distorted section (Thr-
109(2.54) to Thr-117(2.62), one turn above and below
Pro-113(2.58)). The replacement sequence selected consisted of
residues Leu-144 to Tyr-155 (including anchor regions; sequence
homology toKORsequence60%; rootmeansquare fit toanchor
regions  0.12 Å) of the E chain of Protein Data Bank structure
1RP3, an all-helical RNA polymerase  factor. SCWRL version 3
was used once again to assign side chain geometries to the newly
substituted backbone, and theKORmodelwas energy-minimized
under the same conditions as described above to generate what
will subsequently be called the TM2-rotated KOR model. After
minimization of the TM2-rotated KORmodel, a helix irregularity
once again appeared at Pro-113(2.58). A crystal structure (Protein
Data Bank code 1U1I, residues Thr-1031 to Tyr-1043) was found
that exhibited the samehelix irregularity as theTM2-rotatedKOR
model (not shown), suggesting that this feature does occur.
The automateddockingprogramGOLD(24, 25) (version3.0.1)
was used to dock salvinorin A into the receptor site of the TM2-
rotated KORmodel. The CONCORD routine within SYBYL was
used to assign initial conformations to salvinorin A. Genetic algo-
rithmandannealingparameters corresponding to the3 speedup
option in GOLD were used, and 30 individual genetic algorithm
runs were performed. A 20.0-Å radius about the Tyr-313(7.36)
side chainoxygenatomwasused todefine the receptor site.Cavity
detection and ring corner flipping were enabled, and the Gold-
Score fitness function was used to rank the docked solutions.
To explore the possible interaction of the cognate residue of
Val-118(2.63) in the DOR (Lys-108(2.63)) and the MOR (Asn-
129(2.63)) with the E2 loop, molecular dynamics (MD) simula-
tions were performed. Initial V118(2.63)K and V118(2.63)N
KOR mutants were generated from the TM2-rotated KOR
model by mutating the 2.63-position in silico. As in our previ-
ouswork (10), theN terminuswas removed, because it has been
previously shown that the N-terminal region is not necessary
for ligand binding to MOR (26, 27) and that the lengths and
sequence homology of the KOR and rhodopsin loops bear little
similarity. For each KOR mutant, an MD simulation was per-
formed for 100 ps using the default settings of the MD routine
within SYBYL, except that snapshotswere taken every 25 fs rather
than every 5 fs. Additionally, the energy setupwas the same as that
described above for energy minimization. All residues except the
E2 loop (Val-195 toAsp-223),Cys-131, andeitherLys-118(2.63)or
Asn-118(2.63) were maintained as an aggregate.
For the models presented here, the PROTABLE facility
within SYBYL was used to identify and adjust sites of unusual
and sterically clashing side chain geometries. All molecular
modeling was carried out on IRIX 6.5-based Silicon Graphics,
Inc. workstations.
Data Analysis—Statistical comparisons were made using one-
way analysis of variance followedbyDunnett’spost hoc analysis for
comparison of mutant or chimeric receptors with wild-type KOR
as indicated. Heterologous competition and saturation binding
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analyses as well as statistical comparisons were completed using
GraphPad Prism 4.03 (GraphPad Software, Inc., San Diego, CA).
RESULTS
Identification of Domains Essential for Salvinorin A Binding to
KOR Revealed by Analysis of Chimeric Opioid Receptors—
Our previous studies have demonstrated that the lipid-like hal-
lucinogen salvinorin A selectively and potently binds to the
peptidergic KOR, with no significant affinity for the DOR or
MOR subtypes (5). We took advantage of this selective binding
profile to identify receptor domains involved in the subtype-selec-
tive binding of salvinorin A to KOR. To this end, a series of chi-
meric opioid receptors were constructed using an overlapping
PCR strategy to combine transmembrane and loop segments of
the KOR,DOR, andMOR (Fig. 1). All chimeras were expressed at
moderate to high levels (0.74–64 pmol/mg protein) inHEK 293T
cells and retained high affinity for the antagonist [3H]diprenor-
phine, which was used to label these chimeras in competition
binding studies (Table 1).
To elucidate the receptor regions that are important for salvi-
norin A selectivity, we first deter-
mined the affinity constants (Ki) of




DOR(TM5–7) chimera exhibited an
affinity for salvinorin A comparable
with wild-type KOR, whereas the
affinity of salvinorin A at the
DOR(TM1–4,E2L)-KOR(TM5–7) chi-
mera was similar to wild-type DOR
(Table 1 and Fig. 2A). The affinity of
the nonselective antagonist naloxone
for the KOR(TM1–4,E2L)-DOR(TM5–7)
and DOR(TM1–4,E2L)-KOR(TM5–7)
chimeras was comparable with wild-
type KOR and DOR, respectively
(Table 1 and Fig. 2B), suggesting that
the lack of salvinorin A binding at the
DOR(TM1–4,E2L)-KOR(TM5–7) chi-
mera did not result from a global dis-
ruptionof the receptor ligandbinding
pocket.
To further identify specific recep-
tor domains within the proximal
FIGURE 1. Schematic diagrams of wild-type KOR, DOR, MOR, and selected cross-subtype chimeras. Ten func-
tional chimeras between KOR (black), DOR (white), and MOR (hatched) were constructed as described under “Exper-
imental Procedures.” The KOR-DOR chimeras included KOR(TM1–4,E2L)-DOR(TM5–7) and DOR(TM1–4,E2L)-KOR(TM5–7) and
the single TM chimeras, including KOR-DOR(TM1), KOR-DOR(TM2), KOR-DOR(TM4), and KOR-DOR(E2L), in which the
indicated receptor domains of DOR were substituted into KOR. The KOR-DOR(TM2) chimera also contained a similar
amino acid mutation (M90L) in the first intracellular loop of KOR. The salvinorin A rescue chimeras included DOR-
KOR(TM1) (not shown), DOR-KOR(TM1,TM2), DOR-KOR(TM2,E2L), and MOR-KOR(TM2,E2L), in which the indicated receptor
domains of KOR were substituted into DOR or MOR as indicated. The DOR-KOR(TM2,E2L) chimera also contained a
similar amino acid mutation (L80M) in the first intracellular loop of DOR. Two additional receptors were constructed
using site-directed mutagenesis in the DOR-KOR(TM2,E2L) and MOR-KOR(TM2,E2L) chimeras to revert the nonconserved
amino acids (Thr-2.55 and Met-2.57) in TM2 of KOR to the analogous residues (Ser-2.55 and Leu-2.57) in wild-type
DOR and MOR. These chimeric/mutant receptors were used to assess more directly the role of Val-2.53 and Val-2.63
in rescuing salvinorin A binding to MOR and DOR.
TABLE 1
Affinity constants (Ki) for salvinorin A and naloxone binding to wild-type KOR, DOR, and MOR and cross-subtype chimeras
Receptor Kda Bmaxa
Salvinorin A Naloxone
Kib Ratioc Kib Ratioc
nM pmol/mg nM nM
KOR 0.15  0.02 6.9  0.3 27.1  4.7 11.9  1.4
KOR(TM1–4,E2L)-DOR(TM5–7) 0.08  0.02 3.2  0.4 18.2  3.0 0.7 5.2  0.8 0.4
DOR 0.40  0.01 4.7  0.2 10,000d,e 350 54.9  6.4d 4.6
DOR(TM1–4,E2L)-KOR(TM5–7) 0.94  0.11 12.3  0.1 10,000d,e 350 74.9  9.2d 6.3
KOR-DOR(TM1) 0.43  0.08 48.9  5.6 14.5  5.8 0.5 22.5  2.5 1.9
KOR-DOR(TM2) 0.82  0.16 22.9  1.4 10,000d,e 350 37.4  2.6d 3.1
KOR-DOR(TM4) 0.16  0.02 48.3  10.2 95.6  21.1 3.5 8.2  0.6 0.7
KOR-DOR(E2L) 0.14  0.05 10.3  0.8 204  55d 7.5 9.9  0.6 0.8
DOR-KOR(TM1) 0.33  0.04 13.9  1.0 5000d,e 180 25.0  3.5 2.1
DOR-KOR(TM1,TM2) 0.31  0.05 64.1  2.9 854  67d 31.5 13.3  2.7 1.1
DOR-KOR(TM2,E2L) 0.06  0.01 0.75  0.01 128  21d 4.7 9.4  1.2 0.8
DOR-KOR(TM2,E2L) T2.55S,M2.57L 0.062  0.002 2.2  0.1 54.3  9.7 2.0 8.12  0.01 0.7
MOR 0.17  0.05 2.0  0.4 1000d,e 37 4.4  0.2 0.4
MOR-KOR(TM2,E2L) 0.048  0.004 0.321  0.003 19.6  2.1 0.7 0.6  0.1 0.1
MOR-KOR(TM2,E2L) T2.55S,M2.57L 0.04  0.01 0.74  0.03 22.4  2.6 0.8 0.27  0.03 0.02
a Saturation binding of 3H	diprenorphine forwild-typeKOR,DOR, andMORand cross-subtype chimeraswas performed in transiently transfectedHEK293T cells. Data shown
are the mean  S.E. of two or three independent experiments performed in duplicate.
b The affinity constants (Ki) for salvinorin A and naloxone were determined by heterologous competition binding using 3H	diprenorphine and increasing concentrations of
unlabeled ligands. Data shown are themean S.E. for at least three independent experiments performed in duplicate. ForKi values of10,000 nM, inhibitionwas less than 50%
with 10 M salvinorin A.
c For each compound, the ratio is Ki(chimera)/Ki(KOR).
d p 
 0.01 compared with wild-type KOR for the indicated ligand (Dunnett’s post hoc one-way analysis of variance).
e Inhibition less than 50%.
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region (TM1–TM4 and the E2 loop) of KOR, we systematically
introduced TM domains from the “salvinorin A-insensitive”
DOR into the “salvinorin A-sensitive” KOR (Fig. 1) and deter-
mined the effects on salvinorin A
binding affinity. The affinity con-
stants for salvinorin A at the KOR-
DOR(TM1) and KOR-DOR(TM4) chi-
meras were not significantly altered
compared with the wild-type KOR
(Table 1), indicating that the substi-
tution of TM1 or TM4 of DOR into
KOR was not sufficient to disrupt
salvinorin A-KOR binding interac-
tions. In contrast, the affinity of
salvinorin A at the KOR-DOR(E2L)
chimera was decreased 8-fold com-
pared with wild-type KOR, and
salvinorin A failed to bind at the
KOR-DOR(TM2) chimera (Table 1
and Fig. 2C). All of these single TM
domain chimeras, including the
KOR-DOR(TM2) chimera, retained
high affinity binding for naloxone
(Table 1 and Fig. 2D), indicating
that the lack of salvinorin A binding
to the KOR-DOR(TM2) chimera was
not caused by a global disruption of
the ligand binding pocket.
Since introduction of TM2 and
the E2 loop of DOR markedly
reduced salvinorin A binding in
KOR, we performed the converse
rescue experiments. In these exper-
iments, “salvinorin A-sensitive”
KOR domains were introduced into
the “salvinorin A-insensitive” DOR
and MOR subtypes (Fig. 1), and we
determined the affinity of salvinorin
A and naloxone. Two additional
receptors were constructed using
site-directed mutagenesis in the
DOR-KOR(TM2,E2L) and MOR-
KOR(TM2,E2L) chimeras to revert the
nonconserved but similar amino
acids (Thr-2.55 and Met-2.57) in
TM2 of KOR to the analogous resi-
dues (Ser-2.55 and Leu-2.57) in
wild-type DOR and MOR (Fig. 3).
These receptors were used to assess
more directly the role of the diver-
gent residues (Val-2.53 and
Val-2.63) in rescuing salvinorin A
binding to MOR and DOR. The
affinity of [3H]diprenorphine for the
MOR-KOR and DOR-KOR rescue
chimeras was modestly increased
(4- and 7-fold) compared with wild-
type MOR and DOR, respectively
(Table 1). The affinity of naloxone at the MOR-KOR(TM2,E2L)
and MOR-KOR(TM2,E2L) T2.55S,M2.57L chimeras was
increased (7- and 16-fold, respectively) compared with wild-
FIGURE 2. Identification of TM2 and the E2 loop as essential domains for subtype selectivity using chi-
meric opioid receptors. Representative competition binding isotherms for salvinorin A and naloxone at
wild-type and various chimeric opioid receptors are shown. The data are presented as the percentage of total
[3H]diprenorphine binding (0.2 nM) in the presence of increasing concentrations of unlabeled salvinorin A (A,
C, and E) and naloxone (B, D, and F) as indicated. Affinity constants (see Table 1) were determined by fitting the
data to a one-site competition model of radioligand binding to a single binding site using Prism 4.03 (GraphPad
Software).
FIGURE 3. Alignment of opioid receptor domains shown to be involved in the selectivity of salvinorin A
binding. Shown are the amino acid sequence alignments for TM2 and the E2 loop of human KOR (P41145), rat
KOR (P34975), human DOR (P41143), mouse DOR (P32300), and human MOR (P35372), with the residue posi-
tions shown in parentheses. The conservative and identical residues are shown in dark and light gray, respec-
tively. The similar residues are highlighted in black, and nonsimilar or weakly similar residues are highlighted in
white. Residues at positions 2.53, 2.55, 2.57, and 2.63 are indicated in boldface type. The sequence alignments
were completed with AlignX, a component of Vector NTI Advance 10.0.1 (Invitrogen).
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type MOR, whereas the affinity of naloxone for the DOR-KOR
rescue chimeras was comparable with wild-type KOR (Table 1
and Fig. 2F).
As shown in Table 1 and Fig. 2E, the substitution of TM1 of
KOR into DOR (DOR-KOR(TM1)) had no significant effect on
salvinorin A affinity compared with wild-type DOR; however,
the substitution of TM1 and TM2 of KOR into DOR (DOR-
KOR(TM1,TM2)) rescued salvinorin A binding to DOR. The
affinity of salvinorin A was increased further at the DOR-
KOR(TM2,E2L) chimera in which TM2 and the E2 loop of KOR
were substituted intoDOR (Table 1). Similarly, the substitution
of TM2 and the E2 loop of KOR into MOR (MOR-
KOR(TM2,E2L)) rescued high affinity salvinorin A binding to
MOR comparable with the wild-type KOR (Table 1). Salvinorin
A binding was also rescued to a comparable degree with the
DOR-KOR(TM2,E2L) T2.55S,M2.57L and MOR-KOR(TM2,E2L)
T2.55S,M2.57L chimeras (Table 1). These observations dem-
onstrate a critical role for TM2 as well as the E2 loop in stabi-
lizing salvinorin A binding interactions in DOR and MOR, but
the 2.55 and 2.57 positions do not appear to be critical sites of
interaction for salvinorin A.
Site-directed Mutagenesis Reveals Two Residues That Confer
Salvinorin A Selectivity—All of the opioid receptors, including
KOR,DOR, andMOR, share significant sequence similarities in
the putative transmembrane domains (28), with 80% homol-
ogy in TM2 and TM3 (Fig. 3). Sequence alignments of selected
species of KOR, DOR, and MOR also revealed that TM1 and
TM4 share 40% sequence identity (not shown), whereas the
E2 loop regions of opioid receptors aremostly divergent (Fig. 3).
Based on the observation that the KOR-DOR(TM2) chimera
lacks the ability to bind salvinorin A and the DOR-
KOR(TM2,E2L) and MOR-KOR(TM2,E2L) chimeras exhibit a sig-
nificant gain in salvinorin A affinity, we focused our attention
on the nonconserved amino acid residues within TM2 of KOR,
including Val-108(2.53), Thr-110(2.55), Met-112(2.57), and
Val-118(2.63) (Fig. 3, shown in boldface type). The amino acid
at position 2.62 (Thr-117) of human KOR is not conserved in
DOR, but the analogous residue in rat KOR (Ala-117(2.62)) is
conserved with DOR Ala-107(2.62) (Fig. 3). Since salvinorin A
binds to the rat KOR with high affinity, we reasoned that the
sequence divergence between human KOR and DOR at posi-
tion 2.62 is not likely to account for the selectivity of salvinorin
A binding. The nonconserved amino acids weremutated one at
a time to the analogous residues in DOR (Ala-98(2.53), Ser-
100(2.55), Leu-102(2.57), and Lys-108(2.63)), and the affinity
constants for salvinorin A and naloxone at wild-type and
mutant KORs were determined.
As shown inTable 2 andFig. 4,A andB, only theV108(2.53)A
and V118(2.63)K mutations caused a statistically significant
decrease in salvinorin A affinity. The V108(2.53)A mutation
decreased salvinorin A 11-fold and naloxone affinity 5-fold,
whereas the V118(2.63)K mutation markedly decreased salvi-
norin A affinity 36-fold but caused only a slight decrease
(3-fold) in the affinity of naloxone compared with wild-type
KOR (Table 2). The double mutation of V108(2.53)A and
V118(2.63)K dramatically decreased salvinorin affinity 200-
fold and naloxone affinity 12-fold (Table 2 and Fig. 4). The
double mutant of KOR also decreased the affinity of [3H]di-
prenorphine 20-fold compared with wild-type KOR (Table 2).
We also utilized site-directedmutagenesis to examine the non-
conserved residues in TM3, which were not examined in our
chimeric studies. Mutation of the nonconserved amino acids in
TM3 of KOR (Ile-133(3.27) and Ile-135(3.29)) to the analogous
residues in DOR (Ala-123(3.27) and Leu-125(3.29)) had negli-
gible effects on the affinity of salvinorin A and naloxone com-
pared with wild-type KOR (Table 2). Taken together, these
findings demonstrate crucial roles for Val-108(2.53) and Val-
118(2.63) inmediating the subtype selectivity of salvinorin A to
KOR.
MolecularModeling PredictsDifferential TM2HelicalOrien-
tations among Opioid Receptor Subtypes—Our initial KOR
model (10) was subsequently modified to incorporate and
account for the experimentally determined binding data pre-
sented here. Mutant KOR models V118(2.63)K and
V118(2.63)N were also created to explore indirect effects that
may be occurring at the DOR andMOR receptors, respectively,
thus preventing salvinorin A from binding at those receptor
mutants. Since the initial model did not sufficiently explain the
involvement of Val-118(2.63) in salvinorin A binding, an extra-
cellular portion of TM2 was rotated so as to position
Val-118(2.63) in a more prominent location in which it might
be accessed from within the receptor binding site.
TABLE 2
Affinity constants (Ki) for salvinorin A and naloxone binding to wild-type and mutant KORs
Receptor Kda Bmaxa
Salvinorin A Naloxone
Kib Ratioc Kib Ratioc
nM pmol/mg nM nM
KOR 0.124  0.004 7.3  1.1 23.5  5.7 8.5  1.1
V108(2.53)A 0.45  0.06 13.2  2.3 269  25d 11.4 45.8  6.9d 5.4
V108(2.53)L 0.11  0.04 25.9  11.1 4.1  0.8 0.2 3.6  0.6 0.4
T110(2.55)S 0.46  0.12 7.8  4.4 28.0  5.3 1.2 15.9  2.2 1.9
M112(2.57)L 0.18  0.03 15.9  1.2 73.5  20.8 3.1 7.8  0.2 0.9
V118(2.63)K 1.47  0.30 21.7  0.6 846  176d 35.9 24.5  2.1 2.9
V108(2.53)A,V118(2.63)K 3.20  0.46 6.1  2.6 5000d,e 200 107  19d 12.5
I133(3.27)A 0.16  0.03 11.2  1.1 19.1  4.6 0.8 12.8  0.4 1.5
I135(3.29)L 0.19  0.03 47.6  11.2 99.1  28.4 4.2 9.6  0.7 1.1
a Saturation binding of 3H	diprenorphine for wild-type and mutant KORs was performed in transiently transfected HEK 293T cells. Data shown are the mean  S.E. of 2–4
independent experiments performed in duplicate.
b The affinity constants (Ki) for salvinorin A and naloxone were determined by heterologous competition binding using 3H	diprenorphine and increasing concentrations of
unlabeled ligands. Data shown are the mean  S.E. of at least three independent experiments performed in duplicate.
c For each compound, the ratio is Ki(mutant)/Ki(KOR).
d p 
 0.05 compared to wild-type KOR for the indicated ligand (Dunnett’s post hoc one-way analysis of variance).
e Inhibition was 50% with 10 M salvinorin A.
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The amount of helical rotation applied to Met-112(2.57) to
Met-121(2.66) was determined visually and with the aid of
wheel plots depicting the lipid- or binding site-exposed status
of these residues (Fig. 5). A simple calculation involving the
Kyte-Doolittle hydropathy index (29)was employed to estimate
the hydrophobicity of the membrane-exposed residues before
and after rotation. In Fig. 5a, residues Phe-114(2.59),
Gln-115(2.60), Thr-117(2.62), andVal-118(2.63) are clearly lip-
id-exposed (Leu-120(2.65) and Met-121(2.66) were not
included, since these residues were considered to be above the
lipid layer at and near the polar head groups of the phospholip-
ids). The hydropathy indices for each of the lipid-exposed res-
idueswere then summed to obtain ameasure of hydrophobicity
(Table 3). Small side chains that were in the interhelical space
and not clearly lipid-exposed were not included in the calcula-
tion. The hydropathy score was also calculated for the lipid-
exposed residues after the rotation (Fig. 5b and Table 3), and
the two values were compared. A helix rotation was considered
to be favorable if the sum of the hydropathy indices was greater
after the rotation than before the rotation, since this would
place side chains with more hydrophobic character into the
lipid bilayer. As Table 3 indicates, helix rotations are favorable
for the KOR V118(2.63)K and V118(2.63)N mutants as well as
DOR andMORbut not for the wild-type KOR. Thesemodeling
results predicted that the rotational flexibility of the extracellu-
lar part of TM2 itself may be responsible for the lack of binding
affinity for the KOR mutant, a prediction experimentally veri-
fied (see below).
Preliminary attempts to dock salvinorin A into the receptor
binding site of the TM2-rotated KOR model using automated
methods indicated that direct interaction between the salvi-
norin A and Val-118(2.63) is not sterically achievable. Binding
modes similar to that previously proposed (10), however, were
found among the docked solutions. In these docked solutions,
the weak hydrogen bond interaction of Tyr-119(2.64) with the
furan oxygen of salvinorin A is disrupted in the TM2-rotated
KOR model (Fig. 5c).
Lacking a binding mode with the direct involvement of Val-
118(2.63), the modeling effort was shifted toward identifying
indirect effects that could give rise to the specificity of salvi-
norin A for KOR. MD simulations were performed with
V118(2.63)K and V118(2.63)N KOR mutants. The outcome of
theseMD runs was quite different for each of the KOR-to-DOR
(V118(2.63)K) and KOR-to-MOR (V118(2.63)N) mutants. For
the V118(2.63)K mutant, the side chain of Glu-209 (E2 loop)
became associated with the Lys-118(2.63) and Trp-124 (E1
loop) side chainswithin the first 5 ps, and this ion pair remained
intact throughout the remainder of theMD trajectory. Interest-
ingly, at the same time the ion pair was being formed, the E2
loop underwent a concerted motion that effectively reorga-
nized the side chain interactions within the loop, modifying the
FIGURE 4. Identification of Val-108 and Val-118 as critical residues for the
subtype selectivity of salvinorin A. Representative competition binding
isotherms are shown for salvinorin A and naloxone at wild-type and mutant
KORs transiently expressed in HEK 293T cells. The data are presented as the
percentage of total [3H]diprenorphine binding (0.2 nM) in the presence of
increasing concentrations of unlabeled salvinorin A (A) and naloxone (B) as
indicated. Affinity constants (see Table 2) were determined by fitting the data
to a one-site competition model of radioligand binding to a single binding
site using Prism 4.03 (GraphPad Software).
FIGURE 5. Molecular modeling and SCAM predict a helical rotation
involved in subtype selectivity of salvinorin A. Wheel plots depict the ori-
entation of the rotated residues (Met-112 to Met-121) in TM2 before the rota-
tions (a) and after the rotations (b) in the wild-type KOR. The gray areas cor-
respond to the inward facing portions of the helix; white areas are outward
facing (toward the lipid membrane). Numbers in blue specify Kyte-Doolittle
hydropathy indices. Leu-120 and Met-121 were not included. c, molecular
models of the KOR wild-type receptor before rotation (green) and after rota-
tion (orange) with salvinorin A docked and energy-minimized in both recep-
tors. The differential orientation of Tyr-119(2.64) is illustrated. For clarity, the
backbone trace of TM1 has been omitted.
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loop backbone conformation (not shown). The loop did not,
however, rise significantly out of the binding pocket. In the
reorganized loop structure, Ser-211 is repositioned such that its
side chain occupies the same space that salvinorinAoccupies in
the previously proposed binding mode, providing a possible
explanation for the lack of salvinorin A binding to DOR. In the
original KORmodel, salvinorin A is closely associated with res-
idues of the E2 loop (Cys-210 to Phe-214); this is consistent
with the observation that the composition of the E2 loop is
important in determining the selectivity of the various opioid
receptors for salvinorin A. In the altered loop structure, an
extensive network of hydrogen bonds was formed among the
charged and polar Asp, Glu, Lys, Arg, and Gln side chains that
are part of the E2 loop (not shown). In contrast, in the MD
simulation of the V118(2.63)Nmutant, the loop remained in its
original position throughout the 100-ps simulation. In this case,
the Glu-209 and Asn-118(2.63) side chains are too far apart to
interact effectively.
SCAM Reveals Differential TM2 Helical Orientations among
Opioid Receptor Subtypes—To further examine the role of TM2
for salvinorin A binding and to test our prediction that TM2 is
rotated, we used SCAM (19–21) to explore possible differences
in the water accessibility and helical orientation of residues in
TM2 of KOR and DOR. Given the apparent indirect role of
Val-2.53 and Val-2.63 in the selective binding of salvinorin A to
KOR, we reasoned that receptor subtype differences at these
loci induce changes in the helical orientation of TM2, thus
resulting in differential access of residues to the water-accessi-
ble salvinorin A binding pocket.
To this end, 13 consecutive residues in the extracellular por-
tion of TM2 in KOR (Leu-120(2.65) to Val-108(2.53)) andDOR
(Leu-110(2.65) to Ala-98(2.53)) were mutated, one at a time, to
cysteine. Saturation binding studies using [3H]diprenorphine
demonstrated that these KOR and DOR cysteine mutants were
expressed atmoderate levels in HEK 293T cells, and the affinity
for [3H]diprenorphine was not markedly altered compared
with wild-type KOR and DOR, although the KORQ115(2.60)C
mutant had a 7-fold decrease in [3H]diprenorphine affinity
(Table 4). Pretreatment with the water-soluble and sulfhydryl-
reactive MTSEA reagent markedly inhibited [3H]diprenor-
phine binding to 5 of the 13 cysteine-substituted KORmutants
(Tyr-119(2.64), Ser-116(2.61), Gln-115(2.60), Met-112(2.57),
and Val-108(2.53)) compared with the C315(7.38)S back-
ground mutation (Fig. 6A) (19). Pretreatment with MTSEA
also significantly inhibited [3H]diprenorphine binding to 6
of 13 cysteine-substituted DOR mutants (Leu-110(2.65), Lys-
108(2.63), Ala-107(2.62), Gln-105(2.60), Phe-104(2.59), and
Leu-102(2.57)) compared with wild-type DOR (Fig. 6B). Inter-
estingly, the inhibition of [3H]diprenorphine binding was
reduced for the L120(2.65)C mutant of KOR and the
T99(2.54)C mutant of DOR following pretreatment with
MTSEA (Fig. 6). These studies revealed a differential pattern of
water-accessible residues in the extracellular portion of TM2 in
KOR and DOR. These SCAM results are entirely consistent
with our molecular modeling studies that predict that a differ-
ential rotation of TM2 in KOR, DOR, and MOR is involved in
the subtype selectivity of salvinorin A.
DISCUSSION
Themajor finding of this paper is that the subtype selectivity
of salvinorin A for KOR over other opioid receptors appears to
be due to helical rotations of TM2, which differentially orient
TABLE 3
The hydropathic sums calculated for the clearly lipid-exposed residues before and after rotation
The Kyte-Dolittle hydropathy index was used to estimate the hydrophobicity of membrane-exposed residues. By removing strongly hydrophilic residues from the
lipid-exposed regions, rotation is favored for the KOR V118K and KOR V118N mutants, DOR, and MOR but not the wild-type KOR.
Before rotation After rotation Difference Rotate?
KOR wild type 2.8 (Phe)  3.5 (Gln)  0.7 (Thr)  4.2 (Val)  2.8 1.6 (Pro)  2.8 (Phe)  0.8 (Ser)  0.7 (Thr)  0.3 3.1 No
KOR V118K 2.8 (Phe)  3.5 (Gln)  0.7 (Thr)  3.9 (Lys)  5.3 1.6 (Pro)  2.8 (Phe)  0.8 (Ser)  0.7 (Thr)  0.3 5.0 Yes
KOR V118N 2.8 (Phe)  3.5 (Gln)  0.7 (Thr)  3.5 (Asn)  4.9 1.6 (Pro)  2.8 (Phe)  0.8 (Ser)  0.7 (Thr)  0.3 4.6 Yes
DOR wild type 2.8 (Phe)  3.5 (Gln)  1.8 (Ala)  3.9 (Lys)  2.8 1.6 (Pro)  2.8 (Phe)  0.8 (Ser) 1.8 (Ala)  2.2 5.0 Yes
MOR wild type 2.8 (Phe)  3.5 (Gln)  4.2 (Val)  3.5 (Asn)  0.0 1.6 (Pro)  2.8 (Phe)  0.8 (Ser)  4.2 (Val)  4.6 4.6 Yes
TABLE 4
Affinity constants (Kd) and Bmax values for 
3H	diprenorphine binding to cysteine substitution mutants of KOR and DOR
Saturation binding of 3H	diprenorphine for wild-type KOR and DOR and cysteine mutants was performed in transiently transfected HEK 293T cells. Data shown are the
mean  S.E. of three or four independent experiments performed in duplicate and were determined by fitting the data to a saturation binding model with radioligand
depletion and sharing nonspecific binding using Prism 4.03 (GraphPad Software, Inc., San Diego, CA). All KOR cysteine mutants contained the C315(7.38)S background
mutation.
Receptor Kda Kmut/Kwild type Bmaxa Receptor Kda Kmut/Kwild type Bmaxa
nM fmol/mg nM fmol/mg
KOR 0.11  0.03 99  17 DOR 0.56  0.22 422  50
L120(2.65)C 0.25  0.04 2.2 71  7 L110(2.65)C 0.40  0.22 0.7 116  12
Y119(2.64)C 0.25  0.05 2.2 131  19 Y109(2.64)C 0.54  0.22 1.0 378  29
V118(2.63)C 0.43  0.11 3.8 140  12 K108(2.63)C 0.20  0.03 0.4 1443  384
T117(2.62)C 0.28  0.08 2.4 129  26 A107(2.62)C 0.26  0.11 0.5 122  11
S116(2.61)C 0.26  0.05 2.3 300  19 S106(2.61)C 0.55  0.26 1.0 332  34
Q115(2.60)C 1.08  0.29 9.4 135  19 Q105(2.60)C 0.37  0.05 0.7 26  4
F114(2.59)C 0.38  0.03 3.3 58  6 F104(2.59)C 0.28  0.09 0.5 16  2
M112(2.57)C 0.40  0.08 3.5 70  1 L102(2.57)C 0.42  0.21 0.7 304  41
T111(2.56)C 0.35  0.03 3.0 263  42 T101(2.56)C 0.20  0.07 0.4 375  54
T110(2.55)C 0.53  0.16 4.6 501  24 S100(2.55)C 0.51  0.22 0.9 636  30
T109(2.54)C 0.44  0.06 3.8 242  55 T99(2.54)C 0.48  0.27 0.8 480  313
V108(2.53)C 0.48  0.13 4.2 188  19 A98(2.53)C 0.45  0.23 0.8 481  230
C315(7.38)S 0.50  0.13 4.3 360  66
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conserved residues for favorable interactions with salvinorin A.
Classically, ligand selectivity amongGPCRs has been conceived
as being created by the differential interaction of selective
ligands with nonconserved residues within a topologically con-
strained binding pocket (13, 30, 31). Our results are important,
because they indicate that ligand selectivity can also be
achieved by changes in the relative orientation of conserved
residues within the binding pocket.
Previous studies have demonstrated that salvinorin A bind-
ing to DOR and MOR is negligible compared with KOR (5, 6),
but themolecular determinants involved in this unique binding
profile have yet to be determined.Our originally proposedKOR
model (10) was examined in the context of the new experimen-
tal data presented here. The primary finding described in this
work is that residues Val-108(2.53) and Val-118(2.63) and the
E2 loop are important determinants of the selectivity of salvi-
norin A for the KOR. The major effect comes as a result of the
KOR to DOR mutation V118(2.63)K, which shows a 36-fold
decrease in the binding affinity of salvinorin A for the mutant
compared with the wild type KOR. In our original model, Val-
118(2.63) is oriented such that the side chain is exposed to the
lipid membrane. If the mutation of Val-118(2.63) is to have a
substantial effect on the binding affinity for a ligand, then it
should be oriented toward the binding site or toward other
structural elements of the receptor and not toward the lipid
membrane. Both bovine rhodopsin and the KOR contain resi-
dues known to introduce regions of flexibility in a rigid helical
structure. Bovine rhodopsin contains an underwound Gly-Gly
sequence (Gly-89-Gly-90), and KOR (as well as many other
aminergic GPCRs) contains a proline residue (Pro-113(2.58))
about halfway downTM2. In our initial KORmodel, the under-
wound backbonewas retained, placingVal-118(2.63) outside of
the binding pocket. Performing the rotation of the extracellular
portion ofTM2corresponds to taking up the slack in the under-
wound region and, in doing so, places Val-118(2.63) closer to
the binding site and also places Tyr-119(2.64) in a different
orientation. After the rotations, Val-118(2.63) was oriented
between the TM2-TM3 interface and the interior binding
pocket of the KOR and was flanked by Tyr-119(2.64) and Trp-
124 (not shown). The SCWRL algorithm adjusted the orienta-
tion of the Tyr-119(2.64) side chain such that it remained ori-
ented toward the interior of the binding cavity. The distance
between the Tyr-119(2.64) side chain oxygen atom and the
furan ring oxygen of salvinorin A increased from 3.6 to 5.1 Å
after the rotation procedure and subsequent minimization,
effectively preventing it from hydrogen bonding with the furan
ring (Fig. 5c). This change is presumably a destabilizing one for
salvinorin A.
As indicated under “Results,” automated docking failed to
find a docked solution, which showed that salvinorin A inter-
acts with Val-118(2.63). Modeling efforts were then turned to
finding possible indirect causes to explain the effect of Val-
118(2.63) analogous residues on the binding of salvinorin A at
DOR and MOR. These were addressed using MD and are dis-
cussed under “Results.” It is tempting to suggest that the lack of
binding affinity of salvinorin A for the DOR is caused by a con-
formational change in the structure of the E2 loop induced by
the analogous residue of KOR Val-118(2.63) (DOR
Lys-108(2.63)). However, if our MD simulations are correct,
this conformational changewould not take place in theMOR.A
more likely scenario is that the rotation of the extracellular
portion of TM2 itself disrupts the binding site of salvinorin A,
resulting in the loss of affinity. When this rotation takes place,
Tyr-119(2.64) in the KOR is reoriented such that its proposed
interactionwith salvinorin A is diminished relative to the unro-
tated helix. Additionally, if salvinorin A were to interact with
other side chains on TM2 (notably Ser-116(2.61)), these would
also be affected by the rotation.
Although residues on TM2 (particularly Val-108(2.53) and
Val-118(2.63)) are important determinants for the selectivity of
salvinorinA forKOR, the E2 loop also is important, as indicated
by the DOR-KOR(TM1,TM2) and DOR-KOR(TM2,E2L) chimeras.
FIGURE 6. SCAM analysis reveals a differential pattern of water accessibility in TM2 for KOR and DOR. Cysteine-substituted mutants of the extracellular
half of TM2 of KOR (A) and DOR (B) were expressed in HEK 293T cells and pretreated with the water-soluble, sulfhydryl-reactive MTSEA reagent at the indicated
concentrations for 5 min. Following pretreatment, cells were washed thoroughly, and [3H]diprenorphine binding (0.2 nM) was determined using whole cell
preparations. The effects of MTSEA pretreatment on [3H]diprenorphine binding were expressed as percentage inhibition. Data shown are the mean  S.E. of
3–11 independent experiments performed in duplicate. The filled bars indicate cysteine mutants for which MTSEA pretreatment resulted in a significant
inhibition of [3H]diprenorphine binding compared with the KOR C315(7.38)S mutant and wild-type DOR, respectively (p 
 0.05, Dunnett’s post hoc one-way
analysis of variance). *, [3H]diprenorphine-specific binding was too low to be accurately determined.
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The substitution of TM2 of KOR into DOR rescued salvinorin
A binding to a much larger degree in the presence of the KOR
E2 loop (Table 1). Substitution of the E2 loop of DOR into KOR
only modestly decreased salvinorin A binding (
10-fold), sug-
gesting that the E2 loop may stabilize binding indirectly. In our
original model, the hydrophobic scaffold of salvinorin A is in
close proximity to Leu-212 of the E2 loop. This residue is con-
served inKOR,DOR, andMOR. It is possible, however, that the
differences in homology among the E2 loops of the opioid
receptors confer different backbone geometries to the loops
and, as a result, the position of Leu-212.
Mutagenesis and molecular modeling studies of the salvi-
norin A-KOR binding complex have identified multiple loci
(Gln-115(2.60), Tyr-119(2.64), Tyr-313(7.36), and Tyr-
320(7.43)) that are critical for stabilizing salvinorin A in the
binding pocket of KOR via hydrogen bonding and hydrophobic
interactions (9, 10). Our recent mutagenesis and molecular
modeling studies predict that Tyr-119(2.64) and Tyr-320(7.43)
stabilize salvinorin A binding via hydrogen bonds with the
furan ring, and Tyr-313(7.36) is thought to form hydrophobic
interactions with the methyl group of the 2-acetoxy substitu-
tion (10). Interestingly, the 2-salvinorinyl benzoate derivative
preferentially interacts with the MOR subtype (32). Our bind-
ingmodel predicts the binding of the 2-salvinorinyl benzoate to
KOR would be sterically hindered by Tyr-313(7.36), which is
consistent with the loss of affinity that is observed experimen-
tally (32). Our data imply that Val-2.53 and Val-2.63 induce
changes in the orientation of Tyr-119 and/or other critical res-
idues in the ligand binding pocket that alter the selectivity of
opioid receptors for salvinorin A and derivatives.
Recently, an alternative salvinorinA-KORbindingmodel has
been proposed byKane et al. (9) inwhich salvinorinA is aligned
vertically in the ligand binding pocket. Although this alterna-
tive model utilizes residues similar to those described herein,
there are some qualitative differences in the types of binding
interactions (10). In addition, the alternative model predicts
that Gln-115(2.60), which appears to be water-accessible in
KOR (Fig. 6), forms hydrogen bonds with the lactone oxygen(s)
in the salvinorin A backbone (9). Incidentally, it is known that
the 17-deoxy form of salvinorin A has high affinity (Ki  6 nM)
for theKOR (33), whichwould indicate that only the sp3 oxygen
is required. In addition, ligand selectivity at the KOR has been
attributed to TM6; however, the data Kane et al. (9) indicate
that Glu-297(6.58) does not appear to be involved in salvinorin
A binding. Our present data do not support this alternate bind-
ing model for salvinorin A.
Intriguingly, many of the critical salvinorin A binding resi-
dues, including Gln-115(2.60), Tyr-119(2.65), and Tyr-
320(7.43), are conserved in the “salvinorin A-sensitive” KOR
and the “salvinorin A-insensitive” DOR and MOR subtypes.
Our modeling results predict that these conserved residues
exhibit differential accessibility to the salvinorin A binding
pocket among the various opioid receptor subtypes. To bio-
chemically test this prediction, we utilized SCAM to identify
receptor-subtype differences in the water accessibility of resi-
dues in TM2 that line the salvinorin A binding pocket. Indeed,
we identified several key differences in the water accessibility of
residues in TM2 of KOR and DOR. Importantly, the conserved
residue Tyr-119(2.64), which is thought to stabilize salvinorin
A binding via hydrogen bonding with the furan ring of salvi-
norin A (10), is water-accessible in KOR but not in DOR (Fig.
6A). The key residues identified in the present study also exhib-
ited a differential pattern of water accessibility. The
Val-108(2.53) residue is water-accessible in KOR, whereas the
analogous residue (Ala-98(2.53)) in DOR is not. This is intrigu-
ing, since Val/Ala-2.53 is positioned on the cytoplasmic side of
the proline kink. Presumably, significant rotation of the cyto-
plasmic side of TM2 would be undesirable, since it would dis-
rupt the interaction of Asp-2.50 with Asn-1.50 and/or Asn-
7.49. Thus, Ala-98(2.53) in DOR might simply be obscured by
the side chain of another nearby residue, rendering it sterically
inaccessible to MTSEA. Conversely, the Lys-108(2.63) locus is
water-accessible in DOR, but Val-118(2.63) of KOR is not
accessible. In addition, SCAM analysis of TM7 demonstrated
that the conserved residue Tyr-320(7.43), which is located in
the binding site crevice of KOR and is critical for salvinorin A
binding (9, 10, 21), is water-accessible in KOR but not in DOR
(21).
Prior SCAManalysis of TM7has also suggested that the non-
conserved residue (Tyr-313(7.36)), which is known to interact
with salvinorin A, is not water-accessible in KOR or DOR (21),
although quite recent studies in our laboratory suggest that
Tyr-313(7.36) has some degree of water accessibility.3
In summary, biochemical studies support the hypothesis that
sequence divergence at the Val-2.53 and Val-2.63 loci in KOR,
DOR, andMOR results in a differential pattern of residues that
would have access to the salvinorin A binding pocket, thus pre-
cluding salvinorin A binding to DOR andMOR. The selectivity
of salvinorin A for KOR over DOR andMOR is probably due to
a rotation of the extracellular portion of TM2 when compared
with the KOR. This rotation is predicted to disrupt the previ-
ously proposed salvinorin A binding site (and Tyr-119 in par-
ticular), thus accounting for the loss of affinity of salvinorin A
for theDOR andMOR. These findings support a novelmode by
which subtype selectivity for GPCR ligands is induced by a
change in the topology of conserved residues within a common
binding pocket.
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